Company DMK Pharmaceuticals Corporation

DMKPQ

US00547W3079

Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals

Delayed OTC Markets Other stock markets 10:31:06 2024-04-26 am EDT			5-day change	1st Jan Change
0.036 ^USD	0.00%		-28.43%	-94.86%

Apr. 11	North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	DJ
Apr. 04	North American Morning Briefing : Focus Turns to -2-	DJ

DMK Pharmaceuticals Corporation, formerly Adamis Pharmaceuticals Corporation, is a commercial stage neuro-biotech company. The Company is focused on developing therapies for opioid use disorder (OUD) and other neuro-based conditions. The Companyâs commercial products approved by the United States Food and Drug Administration (FDA) include ZIMHI (naloxone) injection for the treatment of opioid overdose, and SYMJEPI (epinephrine) Injection for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It has a library of approximately 750 small molecule neuropeptide analogues and a differentiated pipeline. The Companyâs lead clinical-stage product candidate, DPI-125, is being studied as a treatment for OUD. The Companyâs other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinsonâs disease.

Number of employees: 12

USD in Million	2021	Weight	2022	Weight	Delta
Drug Development and Commercialization 100.0 %	2	100.0 %	5	100.0 %	+115.34%

USD in Million	2021	Weight	2022	Weight	Delta
United States 100.0 %	2	100.0 %	5	100.0 %	+115.34%

Managers	Title	Age	Since
Ebrahim Versi CEO	Chief Executive Officer	71	23-05-24
Seth Cohen DFI	Director of Finance/CFO	42	23-10-15
Robert H. Uhl IRC	Investor Relations Contact	-	-
John Dorbin LAW	General Counsel	53	23-10-18
Thomas H. Moll PRN	Corporate Officer/Principal	58	09-04-21

Members of the board	Title	Age	Since
Howard Birndorf BRD	Director/Board Member	74	19-08-25
Ebrahim Versi CEO	Chief Executive Officer	71	23-05-24
Vickie Reed BRD	Director/Board Member	62	22-05-23
Jannine Versi BRD	Director/Board Member	38	23-05-24
Meera Desai BRD	Director/Board Member	45	21-09-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	10,109,520	9,167,003 ( 90.68 %)	7,470 ( 0.0739 %)	90.68 %

Name	Equities	%	Valuation
Versi Group LLC 8.972 %	906,394	8.972 %	47 132 $
JPMorgan Securities LLC 1.051 %	106,209	1.051 %	5 523 $
Wells Fargo Bank NA 0.9920 %	100,214	0.9920 %	5 211 $
Geode Capital Management LLC 0.7038 %	71,098	0.7038 %	3 697 $
Tower Research Capital LLC 0.6454 %	65,203	0.6454 %	3 391 $
BlackRock Institutional Trust Co. NA 0.3834 %	38,735	0.3834 %	2 014 $
Vanguard Group, Inc. (Subfiler) 0.3365 %	33,990	0.3365 %	1 767 $
Virtu Financial LLC 0.2196 %	22,185	0.2196 %	1 154 $
G1 Execution Services LLC 0.2003 %	20,237	0.2003 %	1 052 $
Two Sigma Securities LLC 0.1788 %	18,059	0.1788 %	939 $

Name	Equities	%	Valuation
Lincoln Park Capital LLC 100.00 %	3,000	100.00 %	156 $

Name	Equities	%	Valuation
Jannine Versi -	1,941	-	101 $
Versi Group LLC -	1,212	-	63 $

DMK Pharmaceuticals Corp.

11682 El Camino Real Suite 300

92130, San Diego

+858 997 2400

http://www.adamispharmaceuticals.com

address DMK Pharmaceuticals Corporation(DMKPQ)

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
DMK PHARMACEUTICALS CORPORATION	-94.86%	363K
ELI LILLY AND COMPANY	+26.03%	653B
NOVO NORDISK A/S	+26.54%	556B
JOHNSON & JOHNSON	-6.57%	354B
MERCK & CO., INC.	+20.22%	331B
ABBVIE INC.	+4.20%	296B
ASTRAZENECA PLC	+12.85%	233B
NOVARTIS AG	+5.59%	201B
ROCHE HOLDING AG	-9.53%	193B
AMGEN INC.	-6.21%	144B

Other Pharmaceuticals